Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Software Streamlines, Reduces Costs to Develop and Market Medical Device Technologies

By HospiMedica International staff writers
Posted on 30 Apr 2009
Preliminary due diligence and fund development of new medical device technologies can cost up to US$75,000 and take up to three months. More...
But innovators, device manufacturers, service providers, venture capital firms, researchers, healthcare providers, and others now have access to a new online membership community with software that shortens this process to about 90 minutes for only a few thousand dollars, according to the software developer.

E-Zassi (Fernandina, FL, USA) Chief Executive Officer Peter M. von Dyck, remarked, "Not knowing critical details can dramatically hinder a technology from being successfully funded, licensed, developed, or commercialized." These critical details, according to Mr. von Dyck, include: a new technology's probable regulatory classifications; the associated clinical endpoints to support the safety and marketing claims to earn market clearances; early stage clarity on the reimbursement and market landscape; and identification of material manufacturing, distribution, and sales burdens.

E-Zassi dot com is predictive decision-support software that provides rapid due diligence, triaging, and assessment of new medical device innovations. Members can extract critical technical and business-related traits and attributes for a deep analysis and forecast of the opportunities and potential challenges that may be encountered from time of invention throughout all development and commercialization phases. Development and commercially related outputs that are critical include: technology transfer; business development; market and commercial analysis; due diligence and portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants.

All e-Zassi online elements are uniquely categorized and organized among thousands of Device Network Attributes (DNA) the company identified over several years. "We now know how this business and technology 'DNA' can be leveraged by the members in the e-Zassi community to rapidly identify synergistic partners and technologic opportunities," stated Mr. von Dyck. "Empowering our members to leverage these vital attributes on a private online community materially enhances search/match relevancy on a level not available on any other existing network, which helps lower costs, save time, and enhance success rates."

E-Zassi.com is a subscription-based online community and Software as a Service (SaaS) company that was spun off Zassi Medical Evolutions, a privately held company focused on innovation and development in medical devices.

Related Links:

e-Zassi



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.